Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-1335
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma ; volume:148 ; number:1 ; day:6 ; month:11 ; year:2021 ; pages:177-190 ; date:1.2022
Journal of cancer research and clinical oncology ; 148, Heft 1 (6.11.2021), 177-190, 1.2022
- Creator
-
Zinzani, Pier Luigi
Minotti, Giorgio
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00432-021-03833-x
- URN
-
urn:nbn:de:101:1-2022042520120780550950
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zinzani, Pier Luigi
- Minotti, Giorgio
- SpringerLink (Online service)
Other Objects (12)
Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss
Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma
Targeting CD22 for B-cell hematologic malignancies
The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis
Aberrant cell cycle regulatory ubiquitin networks in B-cell malignancies
CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients
Rapid identification of early infections in febrile patients after CD19 target CAR-T cell therapy for B-cell malignancies
Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting
Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
MIP3α as an early prognostic predictor for patients with B-cell malignancies receiving CD19/CD22-redirected CAR-T cell cocktail therapy
Mechanisms of B-cell antigen receptor activation in lymphoid malignancies
Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss
Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma
Targeting CD22 for B-cell hematologic malignancies
The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis
Aberrant cell cycle regulatory ubiquitin networks in B-cell malignancies
CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients
Rapid identification of early infections in febrile patients after CD19 target CAR-T cell therapy for B-cell malignancies
Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting
Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
MIP3α as an early prognostic predictor for patients with B-cell malignancies receiving CD19/CD22-redirected CAR-T cell cocktail therapy
Mechanisms of B-cell antigen receptor activation in lymphoid malignancies
Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss
Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma
Targeting CD22 for B-cell hematologic malignancies
The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis
Aberrant cell cycle regulatory ubiquitin networks in B-cell malignancies
CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients
Rapid identification of early infections in febrile patients after CD19 target CAR-T cell therapy for B-cell malignancies
Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting
Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
MIP3α as an early prognostic predictor for patients with B-cell malignancies receiving CD19/CD22-redirected CAR-T cell cocktail therapy